CorMedix (CRMD) Stock Analysis & Winston Score

CorMedix is a small biotechnology company that makes a medical solution used to prevent dangerous infections in patients who need dialysis. Its main product is DefenCath, a catheter lock solution that is flushed into the tubes connecting patients to dialysis machines to stop bacteria from growing inside them. The company sells DefenCath to dialysis clinics and hospitals across the United States. CorMedix makes money by selling DefenCath directly to healthcare providers and through distribution partners. The product received FDA approval in late 2023, making it the first and only FDA-approved catheter lock solution of its kind in the U.S., which gives the company a meaningful regulatory moat in this niche market. The company is still in the early stages of building out its commercial presence, so its key growth driver is expanding adoption among the roughly 500,000 dialysis patients in the U.S. — though dependence on a single product remains its biggest risk.